Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday, August 2nd.
Several other brokerages have also issued reports on ENDP. Cantor Fitzgerald set a $12.00 target price on shares of Endo International and gave the company a “hold” rating in a research note on Monday, July 23rd. Zacks Investment Research cut Endo International from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. Deutsche Bank set a $10.00 price objective on Endo International and gave the company a “buy” rating in a research report on Friday, June 1st. BidaskClub cut Endo International from a “sell” rating to a “strong sell” rating in a research report on Friday, April 6th. Finally, Mizuho cut Endo International from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $12.00 to $7.00 in a research report on Wednesday, April 4th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Endo International has a consensus rating of “Hold” and an average target price of $11.64.
Shares of Endo International traded down $0.18, reaching $15.65, during midday trading on Thursday, according to Marketbeat.com. The company’s stock had a trading volume of 5,182,009 shares, compared to its average volume of 5,366,320. The company has a debt-to-equity ratio of -132.64, a current ratio of 1.07 and a quick ratio of 0.88. Endo International has a one year low of $5.27 and a one year high of $17.34. The company has a market capitalization of $3.54 billion, a P/E ratio of 4.08, a PEG ratio of 6.29 and a beta of 0.49.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Wednesday, August 8th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The business had revenue of $714.70 million for the quarter, compared to the consensus estimate of $679.72 million. During the same period in the previous year, the firm earned $0.93 EPS. The business’s revenue for the quarter was down 18.4% on a year-over-year basis. analysts anticipate that Endo International will post 2.6 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENDP. Xact Kapitalforvaltning AB grew its holdings in Endo International by 22.2% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 35,715 shares of the company’s stock worth $337,000 after acquiring an additional 6,500 shares during the last quarter. Diamond Hill Capital Management Inc. grew its position in shares of Endo International by 1.0% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after buying an additional 10,600 shares during the last quarter. Neuburgh Advisers LLC grew its position in shares of Endo International by 84.2% in the 1st quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after buying an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC grew its position in shares of Endo International by 83.9% in the 1st quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock worth $245,000 after buying an additional 18,800 shares during the last quarter. Finally, Tyers Asset Management LLC grew its position in shares of Endo International by 84.2% in the 1st quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock worth $274,000 after buying an additional 21,084 shares during the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: Diversification in Your Portfolio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.